Evidence map›Paper›PMID 28432326›Full record

Trial reportScientific reports2017

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection.

Yufei Wang, Trevor Whittall, Stuart Neil, Gary Britton, Mukesh Mistry, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Xuesong Yu and 6 more

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Functional Antigen-Specific CD8 TEuropean journal of immunology · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Yufei WangMucosal Immunology Unit, Kings College, London, UK.
Trevor WhittallMucosal Immunology Unit, Kings College, London, UK.ORCID http://orcid.org/0000-0002-2189-3675
Stuart NeilDepartment of virology, Kings College, London, UK.
Gary BrittonMucosal Immunology Unit, Kings College, London, UK.
Mukesh MistryMucosal Immunology Unit, Kings College, London, UK.
Supachai Rerks-NgarmDepartment of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
Punnee PitisuttithumFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Jaranit KaewkungwalFaculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sorachai NitayaphanArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Xuesong YuStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center Seattle, Washington, USA.
Alicia SatoStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center Seattle, Washington, USA.
Robert J O'ConnellUS Military Research Program, Walter Reed Army Institute of Research, Silver Spring, USA.
Nelson L MichaelUS Military Research Program, Walter Reed Army Institute of Research, Silver Spring, USA.
Merlin L RobbUS Military Research Program, Walter Reed Army Institute of Research, Silver Spring, USA.
Jerome H KimUS Military Research Program, Walter Reed Army Institute of Research, Silver Spring, USA.
Thomas LehnerMucosal Immunology Unit, Kings College, London, UK. Thomas.lehner@kcl.ac.uk.
King's College London · GBFred Hutch Cancer Center · USMahidol University · THWalter Reed Army Institute of Research · USArmed Forces Research Institute of Medical Science · THHenry M. Jackson Foundation · USInternational Vaccine Institute · KRKing's College - North Carolina · USMinistry of Public Health · TH

Funding

Medical Research Council G0801937
6 · The paper itself

Abstract

HIV infection affects 37 million people and about 1.7 million are infected annually. Among the phase III clinical trials only the RV144 vaccine trial elicited significant protection against HIV-1 acquisition, but the efficacy and immune memory were inadequate. To boost these vaccine functions we studied T stem cell memory (TSCM) and innate immunity. TSCM cells were identified by phenotypic markers of CD4

Indexed as

Immunity, InnateImmunologic MemoryAIDS VaccinesCD4-Positive T-LymphocytesHIV-1HIV InfectionsHumansStem CellsAIDS Vaccines

Identifiers

PMID28432326
PMCPMC5430909
OpenAlexW2606778173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.